Drug intelligence / Profile preview

Yang Pa Fang

Development stage: Preclinical
Lead developer: Beijing University of Chinese Medicine East Hospital
Administration: Oral, Topical, Inhalation, Sublingual

Overview

Yang Pa Fang is a traditional Chinese medicine (TCM) formula under investigation for the treatment of Parkinson's disease. Preclinical studies have demonstrated its ability to improve behavioral and pain symptoms in animal models of Parkinson's disease. Its proposed mechanism of action involves modulating brain neurotransmitter metabolism, specifically by reducing the apoptosis of nigrostriatal neurons, alleviating structural damage to these neurons, increasing dopamine levels, and enhancing the activity of tyrosine hydroxylase, an enzyme crucial for dopamine synthesis.

Other names: 养帕方

Targets

TH (Tyrosine hydroxylase)

Beyond the preview

Go deeper on Yang Pa Fang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yang Pa Fang.

Explore the full profile